Winlevi is the FDA-approved standardized cream for acne in patients age 12 and older. Topical spironolactone is a compounded, non-approved treatment with limited testing.
Winlevi means clascoterone cream 1%, a topical androgen-receptor inhibitor that targets hormones in skin. It blocks androgen signals in oil glands to lower sebum and inflammation. Topical spironolactone aims at a similar hormonal path but lacks standardized manufacturing, dosing, and review.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the original research from NIH — Use this page to review the original research.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- How does Winlevi work?
- What is topical spironolactone?
- What does the evidence show?
- Which option fits your needs?
How does Winlevi work?
Clascoterone competes with androgens, especially DHT, for binding in sebaceous glands and hair follicles. That action limits sebum production and inflammation. According to the Cassiopea announcement reported by Practical Dermatology, it was the first acne drug with a new mechanism in nearly 40 years read the approval report. The FDA approved Winlevi on Aug. 26, 2020 for acne vulgaris in patients 12 and older, as noted in the FDA approval notice.
It is first-in-class for topical androgen-receptor inhibition. Approval means its safety and efficacy received formal FDA review. Labeling directs a thin uniform layer twice daily, morning and evening. According to the DailyMed label, common reactions are redness, itching, and scaling or dryness in 7-12% of patients see the current Winlevi label. The same label reported reversible HPA-axis suppression in 1 of 20 adults and 2 of 22 adolescents in a 2-week test.
What is topical spironolactone?
Topical spironolactone is a pharmacy-made preparation, not a manufactured acne product. It is dispensed as a cream, gel, or solution mixed for one patient. It has no FDA approval for acne. That status means no FDA review for acne safety or efficacy.
It also has no standardized pharmacokinetics. Strength, base, absorption, and stability can differ by pharmacy and batch. Doctors who prescribe it write an individualized prescription. A compounding pharmacy then prepares the formula. Patients cannot buy an identical version off the shelf.
What does the evidence show?
Published support for topical spironolactone is small and mixed. Reports describe about six small trials totaling roughly 193-195 patients. Formulas included 5% cream or gel, 2% solution, and 1% nanogel. Some studies reported fewer lesions.
Other results conflicted. Small size, varied vehicles, and short follow-up limit firm dosing guidance. Dermatology guidelines reflect that gap. According to Dermatology Times reporting on the AAD's 2024 acne guidelines, the group conditionally recommended topical clascoterone and oral spironolactone or hormonal therapy but made no recommendation for compounded topical spironolactone review the guideline summary. The split points to stronger evidence for the listed options.
Which option fits your needs?
Winlevi suits readers who want a standardized prescription with labeled dosing and warnings. It is commercialized in the U.S. and Canada by Sun Pharma under license from Cassiopea. Each tube should match the approved formula.
Topical spironolactone suits only readers whose dermatologist sees a specific reason to try a compounded formula. Expect more pharmacy calls, possible refills delays, and batch-to-batch variability. Ask these practical questions before you decide: Bring your acne history, current retinoids or benzoyl peroxide, pregnancy plans, and sensitive-skin issues to the visit. Ask how Winlevi fits with other topicals and what follow-up interval the practice uses.
- Am I 12 or older and able to use a twice-daily cream?
- Do I need a standardized label with known irritation rates?
- Will my pharmacy compound spironolactone, and what base and strength will it use?
- How will we judge progress and stop if irritation or no improvement occurs?